Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. BREAKOUTS..RUNNERS AND HOT PENNIES Message Board

$MNTR  Mentor Capital Cancer Index Gains 32%, A

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36165
Posted On: 03/15/2013 3:23:25 PM
Avatar
Posted By: The Pit Bull


$MNTR  Mentor Capital Cancer Index Gains 32%, Adds Galena, Inovio, Vical and NewLink Genetics



San Diego, CA -


Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013  it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation  immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.


Year-to-date, the now fifteen Cancer Index members have posted an average 32% gain (161% Annualized).  This is more than double the 15% average YTD appreciation of the NASDAQ, S&P, and NYSE Biotech Indices.


The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first ten weeks of 2013 follow: Galena Biopharma Corporation +39.87%, NewLink Genetics Corporation +0.08%,  Vical Incorporated +43.30%,  Inovio Pharmaceuticals, Inc. +7.65%, Dendreon (NASDAQ NDN) +10.40%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +40.10%,  Agenus (NASDAQ:AGEN) +6.59%,  Oncothyreon (NASDAQ:ONTY) +15.63%, Biovest International (Pink Sheets:BVTIQ) -56.00%, Celldex Therapeutics (NASDAQ:CLDX) +78.24%, Northwest Biotherapeutics (NASDAQ:NWBO) +17.96%, CEL – SCI Corp. (NYSE MKT:CVM) -4.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets VCT) +40.18% and Advaxis, Inc. (OTCBB:ADXS) +199.67%  -  all for an average 2013 YTD gain of +31.85%.  (Annualized rate: 161.48%).


Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009.  Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at   www.MentorCapital.com .   


Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.




(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us